Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:ALXO NASDAQ:JBIO NASDAQ:PRQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.11-3.1%$1.19$0.86▼$3.78$245.18M0.364.31 million shs586,941 shsALXOALX Oncology$1.07-3.6%$0.72$0.40▼$2.36$58.37M1.1850,879 shs117,280 shsJBIOJade Biosciences$7.45-0.4%$8.35$6.57▼$105.00$243.09M1.04158,521 shs3,664 shsPRQRProQR Therapeutics$2.27-2.8%$2.20$1.07▼$4.62$238.30M0.36416,211 shs56,220 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-0.87%+0.88%+9.62%-21.92%-52.70%ALXOALX Oncology-9.02%-5.13%+64.01%+107.94%-41.88%JBIOJade Biosciences-3.73%-5.32%-0.13%+5.95%+747,999,900.00%PRQRProQR Therapeutics-4.90%+3.56%+7.37%+31.64%+25.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.11-3.1%$1.19$0.86▼$3.78$245.18M0.364.31 million shs586,941 shsALXOALX Oncology$1.07-3.6%$0.72$0.40▼$2.36$58.37M1.1850,879 shs117,280 shsJBIOJade Biosciences$7.45-0.4%$8.35$6.57▼$105.00$243.09M1.04158,521 shs3,664 shsPRQRProQR Therapeutics$2.27-2.8%$2.20$1.07▼$4.62$238.30M0.36416,211 shs56,220 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-0.87%+0.88%+9.62%-21.92%-52.70%ALXOALX Oncology-9.02%-5.13%+64.01%+107.94%-41.88%JBIOJade Biosciences-3.73%-5.32%-0.13%+5.95%+747,999,900.00%PRQRProQR Therapeutics-4.90%+3.56%+7.37%+31.64%+25.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.75Moderate Buy$8.44664.20% UpsideALXOALX Oncology 2.83Moderate Buy$3.30208.41% UpsideJBIOJade Biosciences 3.00Buy$16.00114.77% UpsidePRQRProQR Therapeutics 3.13Buy$8.00253.20% UpsideCurrent Analyst Ratings BreakdownLatest ALXO, PRQR, ALLO, and JBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025JBIOJade BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$17.00 ➝ $18.008/8/2025PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/4/2025ALLOAllogene TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform8/4/2025ALLOAllogene TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral7/14/2025JBIOJade BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.007/11/2025PRQRProQR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/27/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$8.006/27/2025PRQRProQR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$8.006/16/2025JBIOJade BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K12,258.87N/AN/A$2.01 per share0.55ALXOALX OncologyN/AN/AN/AN/A$2.14 per shareN/AJBIOJade BiosciencesN/AN/AN/AN/A$92.88 per shareN/APRQRProQR Therapeutics$20.46M11.65N/AN/A$0.91 per share2.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$257.59M-$1.11N/AN/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)ALXOALX Oncology-$134.85M-$2.20N/AN/AN/AN/A-115.67%-84.82%11/6/2025 (Estimated)JBIOJade Biosciences-$69.63M-$30.33N/A∞N/AN/A-51.96%-47.65%N/APRQRProQR Therapeutics-$30.04M-$0.46N/AN/AN/A-238.52%-61.25%-28.13%11/6/2025 (Estimated)Latest ALXO, PRQR, ALLO, and JBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ALLOAllogene Therapeutics-$0.28-$0.23+$0.05-$0.23N/AN/A8/13/2025Q2 2025JBIOJade Biosciences-$0.43-$0.86-$0.43-$0.86N/AN/A8/12/2025Q2 2025ALXOALX Oncology-$0.46-$0.49-$0.03-$0.49N/AN/A8/7/2025Q2 2025PRQRProQR Therapeutics-$0.08-$0.14-$0.06-$0.14$5.01 million$4.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/AALXOALX OncologyN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A8.928.92ALXOALX Oncology0.114.524.52JBIOJade BiosciencesN/A10.3110.31PRQRProQR TherapeuticsN/A3.763.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%ALXOALX Oncology97.97%JBIOJade BiosciencesN/APRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%ALXOALX Oncology21.00%JBIOJade Biosciences24.90%PRQRProQR Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310221.88 million192.59 millionOptionableALXOALX Oncology4053.55 million42.31 millionOptionableJBIOJade Biosciences2032.63 million24.50 millionN/APRQRProQR Therapeutics180105.21 million96.38 millionOptionableALXO, PRQR, ALLO, and JBIO HeadlinesRecent News About These CompaniesProQR Therapeutics N.V. $PRQR Shares Sold by Adage Capital Partners GP L.L.C.September 9 at 4:15 AM | marketbeat.comHC Wainwright Expects Lower Earnings for ProQR TherapeuticsAugust 30, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for PRQR FY2025 Earnings?August 30, 2025 | americanbankingnews.comProQR Therapeutics N.V. $PRQR Shares Bought by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.com1,850,348 Shares in ProQR Therapeutics N.V. $PRQR Purchased by Aberdeen Group plcAugust 24, 2025 | marketbeat.comProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by BrokeragesAugust 20, 2025 | marketbeat.comPRQR | ProQR Therapeutics N.V. Stock Price & News - WSJAugust 12, 2025 | wsj.comProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan CapitalAugust 9, 2025 | marketbeat.comProQR Announces Second Quarter 2025 Operating and Financial ResultsAugust 7, 2025 | globenewswire.comProQR Announces Upcoming Presentation at RNA Editing SummitJuly 28, 2025 | globenewswire.comProQR Therapeutics price target raised to $5 from $4 at Evercore ISIJuly 12, 2025 | msn.comProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.comJuly 8, 2025 | investing.comPRQR - ProQR Therapeutics NV Sustainability - MorningstarJuly 3, 2025 | morningstar.comMPRQR - ProQR Therapeutics NV Key Metrics - MorningstarJuly 2, 2025 | morningstar.comMProQR Therapeutics NV (PRQR) Stock Forums - Investing.comJune 29, 2025 | investing.comProQR Therapeutics N.V. (PRQR) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPJune 27, 2025 | finanznachrichten.deProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPJune 26, 2025 | globenewswire.comProQR Therapeutics Reports Q1 2025 Financial ResultsJune 2, 2025 | tipranks.comProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal yearMay 24, 2025 | investing.comProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock NewsMay 13, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Kratos Keeps Climbing After Q2, But Valuation Risk LoomsBy Leo Miller | August 18, 2025ALXO, PRQR, ALLO, and JBIO Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.10 -0.04 (-3.07%) As of 11:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.ALX Oncology NASDAQ:ALXO$1.07 -0.04 (-3.60%) As of 11:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Jade Biosciences NASDAQ:JBIO$7.45 -0.03 (-0.40%) As of 10:29 AM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.ProQR Therapeutics NASDAQ:PRQR$2.26 -0.07 (-2.79%) As of 11:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 What August Labor Data Means for the S&P 500 in September Take the Money and Run: Strategy Stock Looks Tapped Out Why CAVA Is the Dip Buy to Outperform Chipotle What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave Stock MarketBeat Week in Review – 09/01 - 09/05 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
